GlassScriptPhysician profile
Madhavi Gorusu
NPI 1982894697
$207,325.87
in general payments reported to CMS, 2019-2025
66 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $22K · 2021: $18K · 2022: $3,836 · 2023: $21K · 2024: $4,295 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,324 · Food and Beverage: $5,464 · Travel and Lodging: $2,150 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,260.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,324.00 |
| Food and Beverage | $5,464.49 |
| Travel and Lodging | $2,150.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $101.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $41,685.43 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $27,767.24 | 2019-2025 | |
| Celgene Corporation | $24,269.45 | 2019-2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $20,611.18 | 2019-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $18,270.49 | 2019-2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $15,333.65 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $12,721.77 | 2019-2025 | Opdivo, Krazati |
| Adc Therapeutics America, INC. | $10,686.52 | 2023-2025 | |
| Dova Pharmaceuticals | $9,273.45 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $8,294.20 | 2019-2025 | |
| Pfizer INC. | $2,776.91 | 2019-2025 | |
| G1 Therapeutics, INC. | $2,000.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,854.77 | 2019-2025 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Beigene USA, INC. | $1,675.94 | 2020 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,675.46 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $1,201.81 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $588.11 | 2019-2025 | Polivy, Tecentriq, Columvi |
| Janssen Biotech, INC. | $566.86 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $531.26 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Seagen INC. | $247.82 | 2019-2022 | |
| Lilly USA, LLC | $200.87 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $177.13 | 2019-2025 | Onivyde |
| Gilead Sciences, INC. | $176.37 | 2019-2025 | Trodelvy |
| Eisai INC. | $154.13 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.41 | 2019-2024 | |
| Ethicon INC. | $142.39 | 2021 | |
| Daiichi Sankyo INC. | $139.13 | 2019-2025 | Enhertu, Vanflyta |
| Amgen INC. | $132.42 | 2019-2021 | |
| Array Biopharma INC | $129.40 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Glaxosmithkline, LLC. | $116.45 | 2024-2025 | Ojjaara |
| Janssen Pharmaceuticals, INC | $108.40 | 2019-2024 | Rybrevant, Xarelto |
| Exelixis INC. | $105.65 | 2019-2025 | Cabometyx |
| Springworks Therapeutics, INC. | $103.57 | 2025 | Ogsiveo |
| Astellas Pharma US INC | $102.88 | 2024-2025 | Padcev, Vyloy |
| Clovis Oncology, INC. | $97.84 | 2019-2020 | |
| Intuitive Surgical, INC. | $92.55 | 2025 | |
| Myriad Genetic Laboratories, INC. | $90.05 | 2023 | Precisetumor |
| Kite Pharma, INC. | $87.44 | 2020-2025 | Yescarta |
| Sobi, INC | $85.72 | 2024-2025 | |
| Abbvie INC. | $81.95 | 2019-2025 | |
| Pharmaessentia USA Corporation | $81.16 | 2024-2025 | Besremi |
| Stemline Therapeutics INC. | $61.09 | 2024-2025 | Orserdu |
| Caris Mpi, INC. | $56.77 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $51.55 | 2019-2025 | |
| Puma Biotechnology, INC. | $50.83 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $50.71 | 2025 | Orgovyx |
| Tempus Ai, INC | $43.36 | 2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $39.89 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $32.25 | 2024-2025 | Libtayo |
| Epizyme, INC. | $28.74 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $28.18 | 2020 | |
| Foundation Medicine, INC. | $24.58 | 2023 | |
| Tesaro, INC. | $21.44 | 2019 | |
| Verastem, INC. | $20.26 | 2019 | |
| Beone Medicines USA, INC. | $19.71 | 2025 | Tevimbra |
| Dendreon Pharmaceuticals LLC | $19.02 | 2019 | |
| Legend Biotech USA INC. | $16.55 | 2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $16.15 | 2025 | Amtagvi |
| Amag Pharmaceuticals, INC. | $15.47 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.12 | 2025 | Pyrukynd |
| Fortovia Therapeutics, INC. | $14.94 | 2019 | |
| Telix Pharmaceuticals | $14.89 | 2024 | Illuccix |
| Helsinn Therapeutics (U.S.), INC. | $14.17 | 2019 | |
| Tersera Therapeutics LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Gorusu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.